Leptin

Leptin is a 16-kilodalton adipokine secreted by adipocytes in proportion to total fat mass. It serves as a long-range energy-status signal to the hypothalamus, binding primarily to the long isoform of the leptin receptor (LepRb) in the arcuate nucleus and ventromedial hypothalamus.

A single leptin molecule asymmetrically dimerizes two LepRb chains through Site 2 contacts at the cytokine homology region 2 (domains D4-D5) and Site 3 contacts at the immunoglobulin-like domain (D3), burying roughly 750 square angstroms of surface area. This repositions membrane-proximal fibronectin domains and enables transphosphorylation of the constitutively associated Janus kinase 2 (JAK2), initiating four main signaling cascades:

• JAK2/STAT3: the dominant appetite-suppression axis; nuclear STAT3 stimulates POMC expression and inhibits AgRP in arcuate neurons, elevating alpha-MSH tone at the melanocortin-4 receptor • IRS-2/PI3K: sustained energy balance regulation • SHP2/MAPK: additional appetite modulation • AMPK/ACC: coordination of energy expenditure

Net effects are reduced caloric intake and increased energy expenditure. Short-isoform peripheral receptors modulate T-cell activation, insulin secretion, fatty acid oxidation, bone metabolism, and reproductive endocrinology. In common obesity, hyperleptinemia paradoxically coexists with resistance driven by SOCS3-mediated JAK2 inhibition, impaired blood-brain barrier leptin transport, and endoplasmic reticulum stress in hypothalamic neurons.

Leptin's therapeutic evidence divides sharply by indication.

Congenital leptin deficiency: Farooqi and colleagues (JCI, 2002; n=3 children) treated subjects with recombinant human leptin for up to 50 months. All subjects began losing weight within two weeks; over 98% of weight lost was fat mass. Energy intake at standardized test meals fell 45-84%. Fasting insulin, LDL cholesterol, and triglycerides improved. CD4+ T cell counts and interferon-gamma production normalized, establishing leptin's immunological role beyond appetite regulation.

Generalized lipodystrophy: NIH-sponsored open-label, single-arm phase 2 trials (NCT00005905 and NCT00025883) enrolled 105 patients from 2000 to 2014. An earlier 9-patient cohort (Oral et al., 2002) showed a 1.9 percentage-point absolute HbA1c decrease, a 60% median triglyceride reduction, and a 28% fall in liver volume after four months of metreleptin therapy. Three-year NIH data showed HbA1c declining from a mean of 9.4% to 7.0% and triglycerides from approximately 500 mg/dL to 200 mg/dL. Based principally on data from 48 patients in a single-arm open-label pivotal dataset, the FDA approved metreleptin (Myalept) in February 2014 for generalized lipodystrophy. No randomized controlled trial has been conducted for this indication.

Common obesity: Metreleptin has not produced clinically meaningful benefit in common obesity, where circulating leptin is already elevated due to leptin resistance. Trials in this population have consistently failed.

Partial lipodystrophy: Evidence consists of expanded-access program data and small open-label series; results are mixed and use remains off-label in the United States.

Typical dosage: Research/clinical (varies).

Metreleptin (Myalept) is the only FDA-approved leptin replacement therapy. Dosing for generalized lipodystrophy is weight-based and administered subcutaneously once daily:

• Patients 40 kg or less (any sex): starting dose 0.06 mg/kg/day; titrate in increments of 0.02 mg/kg; maximum 0.13 mg/kg/day • Male patients over 40 kg: starting dose 2.5 mg/day; titrate in 1.25-2.5 mg increments; maximum 10 mg/day • Female patients over 40 kg: starting dose 5 mg/day (higher than males, reflecting normally greater physiological leptin levels); titrate in 1.25-2.5 mg increments; maximum 10 mg/day

The drug is reconstituted from lyophilized powder and injected into the abdomen, thigh, or upper arm with daily site rotation. Volumes over 1 mL may be split into two separate injections to limit injection-site discomfort. Dose adjustments target metabolic response (HbA1c, triglycerides) and tolerability, with particular attention to excessive weight loss in pediatric patients.

In the Farooqi congenital leptin deficiency protocol, initial doses were calculated to achieve 10% of the age- and sex-predicted serum leptin concentration, then titrated incrementally toward 150% of predicted levels over subsequent months.

This information describes doses used in clinical trials and in the FDA-approved label for generalized lipodystrophy and is provided for educational purposes only. It does not constitute medical advice. Metreleptin requires specialist endocrinological supervision and is available in the United States exclusively through the Myalept REMS program.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most clinically studied combination is leptin with the amylin analog pramlintide. A 24-week randomized, double-blind proof-of-concept study in overweight and obese subjects found coadministration produced approximately 12.7% mean weight loss, substantially exceeding either agent alone; the combination arm lost roughly 25 pounds versus 17 pounds with pramlintide monotherapy (Roth et al., PNAS, 2008). Preclinical rat data suggest amylin pretreatment partially restores hypothalamic leptin signaling in diet-induced obese animals, potentially explaining the synergistic effect. Neither agent is currently approved for common obesity, and this development program was subsequently discontinued.

GLP-1 receptor agonists combined with leptin have been theorized to exploit complementary gut-brain satiety signaling, but supportive human trial data are absent; evidence is limited to additive effects in preclinical mouse models and is therefore anecdotal for human use.

Dietary modification, exercise, omega-3 fatty acid supplementation, and metformin have been proposed as leptin sensitizers to reduce leptin resistance. Evidence for these approaches is anecdotal or limited to animal models and cannot be extrapolated to human clinical recommendations at this time.

Leptin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Limited efficacy in obese individuals

Adverse effects documented in pivotal metreleptin trials at frequencies above 5% include hypoglycemia (particularly during dose initiation in insulin-treated patients), fatigue, nausea, abdominal pain, alopecia, ovarian cyst formation, extremity pain, and upper respiratory tract infection. Less frequent events include arthralgia, pancreatitis, urinary tract infection, myalgia, and anxiety.

Immunogenicity is a prominent concern. Most patients develop anti-metreleptin antibodies during therapy; neutralizing antibodies were identified in approximately 6% (2 of 33) of tested patients with generalized lipodystrophy in pivotal analyses, resulting in severe infections and worsening metabolic control with rising HbA1c and triglycerides. Total anti-drug antibody rates in some series have been reported as high as 95%, though clinical significance varies.

Lymphoma risk: T-cell lymphoma has been observed in patients with acquired generalized lipodystrophy receiving metreleptin. Critically, the same malignancy has also been diagnosed in comparable patients never treated with the drug, so a causal relationship is unestablished. The FDA issued a boxed warning regarding this association and mandates enrollment in the Myalept REMS program before prescribing.

Additional reported events include anaphylaxis, urticaria, and autoimmune hepatitis.

Contraindications per the FDA label include use in general obesity not associated with congenital leptin deficiency or lipodystrophy, and prior serious hypersensitivity to metreleptin or its excipients. Safety data in pregnancy and lactation are insufficient to establish risk.